

**FDA Office of Generic Drugs Office of Research & Standards (ORS)**  
**Journal Articles Published by External Collaborators and ORS Staff in Fiscal Year 2014**

1. Berg MJ. Lamotrigine, a narrow therapeutic index drug or not? *American Academy of Neurology*. 2014;82 (10).
2. Holt J, Hickey A, Sandell D. From Q2 to QbD: The Influence of Formulation Changes on MDI Performance, *Respiratory Drug Delivery Asia*. 2014;1:33-44.
3. Krieg BJ, Taghavi SM, Amidon GL, Amidon GE. In Vivo Predictive Dissolution: Transport Analysis of the CO<sub>2</sub>, Bicarbonate In Vivo Buffer System, *J Pharm Sci*. 2014 Nov;103(11):3473-90.
4. Krishnaiah YSR, Xu X, Rahman Z, Yang Y, Katragadda U, Lionberger R, Peters JR, Uhl K, Khan MA. Development Of Performance Matrix For Generic Product Equivalence Of Acyclovir Topical Creams, *Int J Pharm*. 2014;475(1-2):110-122.
5. Mitran S, Hickey A, Holt J. Multilinear calibration of lattice Boltzmann pMDI spray simulation, *Respiratory Drug Delivery*. 2014;3:77-682.
6. Saluja B, Delvadia RR, Kim SH, Lee SL. Evaluation of Bioequivalence Criteria for Methacholine-Induced Bronchoprovocation: Bioequivalence Study of Albuterol Sulfate Metered Dose Inhalers, *Respiratory Drug Delivery*. 2014;2:413-416.
7. Saluja B, Li BV, Lee SL. *Bioequivalence for Orally Inhaled and Nasal Products*, New York, NY: Springer. 2014; 369-394.
8. Schroeter JD, Holt J, Asgharian B, Bovet J, Hickey A. Characterization of Particle Size Distributions Respiratory Tract Deposition of Albuterol Sulfate Metered Dose Inhalers, *Respiratory Drug Delivery (RDD) Conference, Fajardo, Puerto Rico*. 2014;2:345-348.
9. Weber B, Lee SL, Delvadia R, Lionberger R, Li BV, Tsong Y, Hochhaus G. Application of the Modified Chi-Square Ratio Statistic in a Stepwise Procedure for Cascade Impactor Equivalence Testing, *AAPS J*. 2014;17(2):370-379.
10. Wong JM, Jones JW, Jiang W, Polli JE, Kane MA. Quantification of lamotrigine in patient plasma utilizing a fast liquid chromatography-tandem mass spectrometry method with backflush technology, *Therapeutic Drug Monitoring*. 2014;37(2):9.
11. Yacobi A, Shah VP, Bashaw ED, Benfeldt E, Davit B, Ganes D, Ghosh T, Kanfer I, Kasting GB, Katz L, Lionberger R, Lu GW, Maibach HI, Pershing LK, Rackley RJ, Raw A, Shukla CG, Thakker K, Wagner N, Zovko E, Lane ME. Current challenges in bioequivalence, quality, and novel assessment technologies for topical products, *Pharm Res*. 2014;31(4):837-846.
12. Zhang H, Li H, Song W, Shen D, Skanchy D, Shen K, Lionberger RA, Rosencrance SM, Yu LX. Completeness assessment of type II active pharmaceutical ingredient drug master files under generic drug user fee amendment: review metrics and common incomplete items, *AAPS J*. 2014;16(5):1132-1141.
13. Zhang X, Lionberger RA. Modeling and simulation of biopharmaceutical performance, *Clin Pharmacol Ther*. 2014;95(5):480-482.
14. Zhang X. *Bioequivalence: Modeling and Simulation*, Springer. 2014; p 395-417.
15. Zheng N, Jiang W, Lionberger R, Yu LX. *Bioequivalence for Liposomal Drug Products*, Springer. 2014; p 275-296.

